Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAISE: Pamrevlumab in Idiopathic Pulmonary Fibrosis
NCT01890265Phase 2Completed
- Sponsor
- FibroGen
- Start
- Jul 2013
- Primary completion
- Nov 2017
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of pamrevlumab in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by FibroGen. Primary endpoint: Change From Baseline in FVC (Percent of Predicted FVC Value) at Week 48. Started Jul 2013; status: completed.
02
Drugs
pamrevlumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01890265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01890265.